These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 226215

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue.
    Reisine TD, Rossor M, Spokes E, Iversen LL, Yamamura HI.
    Adv Biochem Psychopharmacol; 1980; 21():443-50. PubMed ID: 6246753
    [No Abstract] [Full Text] [Related]

  • 3. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK, Rinne JK, Rinne JO, Laakso K, Tenovuo O, Lönnberg P, Koskinen V.
    J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Parkinson's disease: low density and presynaptic location of D3 dopamine receptors.
    Lee T, Seeman P, Hornykiewicz O, Bilbao J, Deck J, Tourtellotte WW.
    Brain Res; 1981 May 18; 212(2):494-8. PubMed ID: 7225883
    [No Abstract] [Full Text] [Related]

  • 6. Developmental relationships between opiate receptors and dopamine in the formation of caudate-putamen patches.
    van der Kooy D.
    Brain Res; 1984 Jun 18; 316(2):300-3. PubMed ID: 6087996
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.
    Kish SJ, Shannak K, Hornykiewicz O.
    N Engl J Med; 1988 Apr 07; 318(14):876-80. PubMed ID: 3352672
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T, Yamaguchi K, Ando T, Shibuya S, Oikawa T, Nakagawa A, Shirane R, Itoh M, Tominaga T.
    J Neurosurg; 2005 Dec 07; 103(6):968-73. PubMed ID: 16381182
    [Abstract] [Full Text] [Related]

  • 14. Neurotransmitter receptor alterations in Parkinson's disease.
    Reisine TD, Fields JZ, Yamamura HI.
    Life Sci; 1977 Aug 01; 21(3):335-43. PubMed ID: 197361
    [No Abstract] [Full Text] [Related]

  • 15. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
    Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, Bankiewicz KS.
    PLoS One; 2017 Aug 01; 12(2):e0169965. PubMed ID: 28166239
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O.
    J Neurol Neurosurg Psychiatry; 1999 Dec 01; 67(6):737-41. PubMed ID: 10567489
    [Abstract] [Full Text] [Related]

  • 19. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K.
    Brain; 2001 Apr 01; 124(Pt 4):784-92. PubMed ID: 11287377
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.